Johnson & Johnson rolls out Shockwave C2 Aero catheter to treat calcified coronary artery disease

Johnson & Johnson (NYSE: JNJ) has moved to expand its intravascular lithotripsy, or IVL, offering for calcified coronary artery disease with the global launch of the Shockwave C2 Aero Coronary IVL Catheter. The announcement, dated May 12, 2026, focuses on a next-generation catheter intended to make it easier for clinicians to navigate complex coronary anatomy and modify hardened plaque inside blocked arteries during percutaneous coronary intervention, a common minimally invasive heart procedure. While some market commentary has lumped the story into a broader “robotics” theme, the underlying product is a cardiovascular catheter technology rather than a mechanical assistance system.

Coronary artery disease (CAD) is driven by progressive buildup of cholesterol deposits that narrow the arteries and reduce blood flow to the heart muscle. Johnson & Johnson says CAD affects an estimated 315 million people worldwide and about 1 in 20 adults over age 20 in the United States. As deposits harden into calcium, conventional angioplasty techniques can struggle to effectively open lesions, especially when vessels are tortuous or severely calcified, conditions that can make standard tools difficult to deliver to the treatment site or difficult to cross through the blockage.

IVL is designed to address that challenge by using ultrasonic acoustic pressure waves delivered from within the vessel. In the company’s description of the Shockwave C2 Aero, the catheter contains an integrated balloon with emitters that fire simultaneously, creating pulses intended to crack hardened calcium in place and help re-establish blood flow. Johnson & Johnson says the catheter’s working length is 138 centimeters and it features two emitters that can fire up to 120 pulses, delivering up to 240 Shockwaves during a procedure. The company positions the C2 Aero as building on Shockwave IVL’s “mechanism of action” while enhancing procedural handling.

In its launch details, Johnson & Johnson ties the new catheter’s design to three practical goals for operators: improved deliverability (getting the device through tight, winding vessels), enhanced lesion crossing (entering dense calcified deposits), and added repositioning capabilities (adjusting the balloon’s position to treat additional lesions). The company says these changes include a more flexible shaft and balloon elements, a tapered tip with a new hydrophilic coating, and a balloon designed to allow easier repositioning within coronary anatomy. In a direct procedural critique of earlier approaches, the company’s quoted interventional cardiologists said earlier catheter generations often required additional ancillary devices for optimal positioning and were more limited in how physicians could move the balloon within the artery.

Johnson & Johnson also offered a commercial timeline for availability. The Shockwave C2 Aero is available in the United States and Japan, and the company said it will be available in Europe and Canada in the coming months. The company further said the next-generation coronary IVL technology will be featured at EuroPCR 2026 in Paris, taking place May 19 through May 22, 2026, reflecting an effort to pair product rollout with clinician education and visibility at a major interventional cardiology conference.

The launch lands as investors and healthcare analysts continue to track the performance of J&J’s cardiovascular device portfolio, particularly its Shockwave business inside the company’s MedTech segment. In Johnson & Johnson’s first-quarter 2026 results materials, the company reported Shockwave sales of $305 million worldwide for the quarter, alongside growth in MedTech overall driven by multiple product lines including Shockwave in Cardiovascular. The C2 Aero rollout is likely aimed at broadening use cases for IVL, particularly where deliverability and lesion crossing limitations have constrained adoption.

Still, the company did not provide new clinical efficacy outcomes, head-to-head data, or pricing and reimbursement terms in the launch announcement. It also did not quantify how many additional procedures might shift to IVL specifically because of the new catheter’s repositioning features. As with most medical device rollouts, the impact on procedure outcomes and payer behavior may take time to become visible in real-world utilization and subsequent financial reporting. The company also framed certain statements as forward-looking, including that the device’s availability expansion and market penetration could evolve based on execution and market conditions.

For what to watch next, clinicians and hospitals will likely focus on training and practical workflow changes, especially how often the new balloon repositioning capability can reduce reliance on additional devices in complex lesions. Investors, meanwhile, will watch whether sales momentum in Shockwave products continues after the launch and whether J&J’s MedTech growth profile increasingly reflects IVL broader adoption across regions. A further signpost could come from conference feedback around EuroPCR and any subsequent regulatory or market access updates for additional geographies.